The second indication of pertuzumab was for the adjuvant treatment of HER2-positive early breast cancer patients at high risk of recurrence in combination with trastuzumab and chemotherapy, based on the phase III APHINITY trial results. The gene discussed is ERBB2; the disease is breast carcinoma.